AstraZeneca's (LSE: AZN) Evusheld (tixagevimab and cilgavimab) has been approved for a second indication in Europe.
Evusheld was previously granted marketing authorization in the European Union (EU) for the prevention of COVID-19 and is already available in a majority of countries in Europe.
It has now been approved in the EU for the treatment of adults and adolescents—aged 12 years and older weighing at least 40 kg—with COVID‑19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze